Everest Organics Ltd

AGM Details

• Date: 30-09-2026; Mode: VC/OAVM; Venue: Hyderabad.
• Start time: 12:00 IST; End time: 12:45 IST.
• Record date: 25-09-2026; Book closure: 25-09-2026.
• Total shareholders on record: 4240; VC participants: 85.

Resolutions and voting

• Ordinary: Adoption of Audited Financial Statements; passed.
• Ordinary: Re-appointment by rotation; passed.
• Ordinary: Ratification of remuneration to Cost Auditors; passed.
• Special: Appointment of Independent Director; passed.

Directors and appointments

• Three independent directors were appointed; approvals granted.
• Re-appointment by rotation approved.

Auditors

• Cost Auditors' remuneration ratified for FY ending March 31, 2027; approved.

AGM details

• AGM on Sep 30, 2026 at 12:00 Noon via VC/OAVM; concluded 12:45 PM.
• Remote e-voting open Sep 27–29, 2026; AGM e-voting also conducted.
• Chairman of the meeting: Independent Director chaired the session.

Resolutions

• Ordinary: adopt Audited Financial Statements for year ended Mar 31, 2026.
• Ordinary: re-appoint Director by rotation (Pachigolla).
• Ordinary: ratify Cost Auditors' remuneration for FY 2027.
• Special: appointment of Narra as Independent Director.
• Special: appointment of Kolli as Independent Director.
• Special: appointment of Banerjee as Independent Director.

Voting results

• No explicit results disclosed in the filing; results to be announced.
• Consolidated results and Scrutinizer's report to be posted on company website.

Dividends

• No dividend proposal or declaration mentioned.

Director changes

• Narra appointed Independent Director.
• Kolli appointed Independent Director.
• Banerjee appointed Independent Director.
• Pachigolla re-appointed by rotation.

Auditors

• Cost Auditors' remuneration for FY 2027 ratified.
• Statutory Auditors attended; no changes disclosed.

Material related party transactions

• No material related party transactions disclosed.

Other material approvals

• No ESOP schemes, amendments, borrowings, or mergers disclosed.

Everest Organics Ltd trading window closed from October 1, 2026 until 48 hours after the declaration of Un-audited financial results for the quarter ended September 30, 2026

Financial highlights

• Revenue from operations: ₹19,615.77 lakh.
• Total income: ₹19,740.42 lakh; PAT: ₹554.65 lakh.
• EBITDA: ₹2,105.72 lakh; PBT: ₹804.68 lakh.
• EPS: ₹5.70; operating margin: 7.43%; net margin: 2.83%.
• Reserves: ₹6,576.77 lakh; paid-up capital after warrants: ₹9.97 crore.
• Dividend declared: none.

Capital structure & liquidity

• Total borrowings (current + non-current): ₹4,993.39 lakh.
• Cash and cash equivalents: ₹10.17 lakh.
• Paid-up capital increased to ₹9.97 crore after warrants conversion.
• Export share of revenue: 15.7% of total revenue.
• Debt-service coverage ratio: 1.73 (per MD&A).

Operations & capacity

• Capex incurred during FY25-26: ₹120 lakh.
• Capacity utilization across portfolio: 80-90%.
• Expenditure on capex funded to support new production block.

Business development

• Capex to upgrade CGMP facilities; enhanced capacity under regulatory pursuit.
• Exports footprint: 85 clients across 48 countries; target 120 clients across 60+ countries in 3 years.
• Strategic focus on CDMO/CMO opportunities.

Governance & leadership

• Independent directors appointed: Narra, Kolli, Banerjee; term 5 years each.
• Venkata Subbarao Pachigolla appointed Whole-Time Director (Nov 12, 2025).
• Shweta Singh appointed Company Secretary (Aug 5, 2025); resigned (Jun 22, 2026).
• Board reconstituted with NRC; Audit Committee chaired by Independent Director.

Dividends & capital allocation

• No dividend declared for FY2025-26; earnings retained for growth.

Audit & controls

• Auditors qualified on capacity approvals; management addressing TSPCB revocation concerns.
• Internal control weaknesses noted; ongoing remediation plan.
• Secretarial audit highlighted governance improvements; compliance ongoing.

Appointments of Independent Directors

• Srikanth Reddy Kolli appointed Independent Additional Director for five years from Aug 14, 2026.
• Subroto Banerjee appointed Independent Additional Director for five years from Aug 14, 2026.
• Committees re-constituted to include the new Independent Directors.

Director Profiles and Compliance

• Srikanth Kolli: 44, ICSI associate member since 2010.
• Srikanth Kolli: 15+ years in corporate secretarial, governance, compliance.
• Srikanth Kolli: Independent Director at ITISH Business Solutions Limited.
• Srikanth Kolli: Not debarred by SEBI or other authorities.
• Subroto Banerjee: 38-year Pharma & Healthcare Strategy Leader.
• Subroto Banerjee: Current President - Strategy & Founding Team, Restory Healthytech.
• Subroto Banerjee: Past roles include President, Strides Shasun; Director-Oncology, Dr. Reddy's.
• Subroto Banerjee: Independent consultant since 2016; advised GLG, Guidepoint, PE/VC.
• Subroto Banerjee: Not debarred by SEBI or other authorities.

Q1 FY27 highlights

• Board approved the unaudited standalone results for quarter ended June 30, 2026.
• Limited Review Report is qualified on Telangana PCB non-compliance matter.
• Total sales turnover for quarter ended 30 June 2026: Rs 4,843.00 lakhs.
• Domestic turnover Rs 3,764.83 lakhs; Export turnover Rs 1,078.23 lakhs.
• Company operates in a single API and intermediates segment.
• Equity shares in unclaimed suspense account as of 30 June 2026.
• Auditor's review is not an audit; scope is limited per SRE 2410.

Meeting Details

• Board meeting scheduled for Friday, August 14, 2026.

Key Agenda Items

• Consider and approve the unaudited financial results for the quarter ended June 30, 2026.
• Consider and note statutory auditors' limited review report on unaudited results for quarter ended June 30, 2026.
• Consider and approve the Board’s Report with annexures for FY 2025-26.
• Fix the time, date, and venue of the 33rd AGM and approve its notice for FY 2025-26.
• Appoint the Scrutinizer for the 33rd AGM.

Other Notes

• Trading window closed from July 01, 2026 until 48 hours after the unaudited results declaration.